Form 4: MAIA Biotechnology Director Ramiro Guerrero Acquires Shares and Warrants

Director Ramiro Guerrero purchased MAIA Biotechnology common stock and warrants on November 1, 2024.

Summary

• Ramiro Guerrero, a director of MAIA Biotechnology, Inc., acquired 88,534 shares of common stock at $2.51 per share on November 1, 2024.
• The purchase increased Guerrero's direct holdings to 408,134.04 shares.
• Guerrero also acquired warrants to purchase 88,534 shares of common stock at an exercise price of $2.259 per share.
• The warrants are exercisable beginning on May 1, 2025, and expire on May 1, 2030.
• The transactions were made pursuant to a Securities Purchase Agreement and the Issuer's 2021 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's purchase of shares and warrants, indicating confidence in the company. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's purchase of shares and warrants can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the director's investment suggests a positive outlook.

Industry Context

Insider transactions are closely watched in the biotechnology industry as indicators of management's confidence in the company's pipeline and prospects. This purchase could be interpreted as a positive signal.

Stakeholder Impact

• The director's purchase could positively influence shareholder sentiment.

Key Dates